Gilead Sciences Leads Our Buy List Higher

The market is somewhat soggy this morning, but our Buy List is being helped by a very strong earnings report from Gilead Sciences (GILD). For the fourth-quarter, the company earned 93 cents a share which easily beat Wall Street’s estimate of 85 cents a share. The company now projects 2010 net products sales of $7.6 billion to $7.7 billion, which translates to a growth rate of 17% to 19% for this year. Wall Street had been forecasting earnings of $3.31 a share for this year, but that will now increase.
The shares have been up by as much as 6.6% today. Here’s a look at the earnings call from Seeking Alpha
The other earnings report was from Stryker (SYK), and that wasn’t so strong. On absolute terms, they did just fine as they almost always do. Stryker earned 82 cents a share but that merely matched Wall Street’s consensus. They reiterated their 2010 outlook of $3.20 to $3.30 per share. I’m fine with that but I guess investors wanted a little more.
Here’s the CEO on CNBC this morning.
Stryker is down about 4% this morning.

Posted by on January 27th, 2010 at 10:38 am

The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.